Inoue T, Inoue Y, Nakamura T, Yoshida A, Takahashi K, Inoue Y, Shimomura Y, Tano Y, Fujisawa Y, Aono A, Hayashi K
Department of Ophthalmology, Osaka University Medical School, Osaka, Japan.
Invest Ophthalmol Vis Sci. 2000 Dec;41(13):4209-15.
The goal of this study was to evaluate the effectiveness of a local plasmid DNA vaccine encoding herpes simplex virus (HSV) type 1 glycoprotein D (gD) or gD-interleukin (IL)-2 (chimeric gene of gD and human IL-2) in preventing murine herpetic keratitis.
Plasmids containing gD (pHSDneo1), gD-IL-2 (pHDLneo1), or vaccine vector (pHSGneo) were injected subconjunctivally with BALB/c mice on days 0 and 7 (90 microgram x 2). Immunization was indicated by positive virus-neutralizing antibody titer, swollen pinna (due to delayed-type hypersensitivity [DTH] reaction), and release of (51)Cr from splenic and/or local cytotoxic effector cells on day 28. In another group of the immunized mice, corneas were challenged with HSV-1 (CHR3 strain, 10 microliter of 3 x 10(6) plaque-forming units [PFU]/ml). Mice were evaluated for clinical signs of epithelial or stromal keratitis on days 1 through 8 and days 10 and 14 or measured on days 2, 4, or 6 for viral titers in the eyes, trigeminal ganglia, and brain.
All gD-DNA-injected mice obtained specific immunity. Furthermore, gD-IL-2-DNA elicited a higher DTH reaction and more vigorous cytotoxic effector cell activity. Stromal keratitis scores were lower for all immunized mice compared with control mice, although the difference in epithelial keratitis scores was not statistically significant. Viral titers in eyes, trigeminal ganglia, and brains were suppressed in all immunized mice.
Local immunization with plasmid DNA encoding gD or gD-IL-2 induces humoral and cellular immunity against HSV-1 and inhibits development of stromal keratitis. gD-IL-2 DNA induces greater cell-mediated immunity than gD DNA alone. A plasmid encoding gD-IL-2 is therefore a promising candidate for a vaccine against HSV-1.
本研究的目的是评估一种编码单纯疱疹病毒1型糖蛋白D(gD)或gD-白细胞介素(IL)-2(gD与人类IL-2的嵌合基因)的局部质粒DNA疫苗在预防小鼠疱疹性角膜炎方面的有效性。
在第0天和第7天,将含有gD的质粒(pHSDneo1)、gD-IL-2的质粒(pHDLneo1)或疫苗载体(pHSGneo)结膜下注射到BALB/c小鼠体内(90微克×2)。在第28天,通过病毒中和抗体滴度呈阳性、耳廓肿胀(由于迟发型超敏反应[DTH])以及脾和/或局部细胞毒性效应细胞释放(51)Cr来表明免疫成功。在另一组免疫小鼠中,用HSV-1(CHR3株,10微升3×10(6)噬斑形成单位[PFU]/毫升)攻击角膜。在第1至8天、第10天和第14天评估小鼠上皮性或基质性角膜炎的临床体征,或者在第2、4或6天测量眼睛、三叉神经节和大脑中的病毒滴度。
所有注射gD-DNA的小鼠都获得了特异性免疫。此外,gD-IL-2-DNA引发了更高的DTH反应和更强的细胞毒性效应细胞活性。与对照小鼠相比,所有免疫小鼠的基质性角膜炎评分较低,尽管上皮性角膜炎评分的差异无统计学意义。所有免疫小鼠眼睛、三叉神经节和大脑中的病毒滴度均受到抑制。
用编码gD或gD-IL-2的质粒DNA进行局部免疫可诱导针对HSV-1的体液免疫和细胞免疫,并抑制基质性角膜炎的发展。gD-IL-2 DNA诱导的细胞介导免疫比单独的gD DNA更强。因此,编码gD-IL-2的质粒是一种有前景的抗HSV-1疫苗候选物。